Effects of isradipine sustained release on platelet function and fibrinolysis in essential hypertensives with or without other risk factors

Cardiovascular Drugs and Therapy

Volumn 10, Issue 2, 1996, Pages 119-123

  Ranieri, G ^b   Filitti, V ^c   Andriani, A ^c   Bonfantino, M V ^c   Lamontanara, G ^c   Cavallo, A ^c   Milani, M ^a   De Cesaris, R ^c  

^a Sandoz Prodotti Farmaceutici Med D   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c NONE

Author keywords

Diabetes mellitus; Fibrinolysis; Hypertension; Israpidine; Platelet functions; Smoking

Indexed keywords

BETA THROMBOGLOBULIN; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE; ISRADIPINE; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOCYTE FACTOR 4;

ADULT; ARTICLE; BLOOD LEVEL; CIGARETTE SMOKING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG ADMINISTRATION; DRUG THERAPY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESSENTIAL HYPERTENSION; EUGLOBULIN LYSIS TEST; FEMALE; FIBRINOLYSIS; HUMAN; HYPERTENSION; LONG TERM CARE; MALE; PHARMACOLOGY; PRIORITY JOURNAL; RISK FACTOR; SINGLE BLIND PROCEDURE; SPHYGMOMANOMETRY; SUSTAINED RELEASE PREPARATION; THROMBOCYTE; THROMBOCYTE AGGREGATION; VEIN OCCLUSION;

ANTIHYPERTENSIVE AGENTS; BETA-THROMBOGLOBULIN; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; FIBRINOLYSIS; HUMANS; HYPERTENSION; ISRADIPINE; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET AGGREGATION INHIBITORS; PLATELET FACTOR 4; SINGLE-BLIND METHOD; SMOKING;

EID: 0030010680     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00823589     Document Type: Article

References (39)

1. Smith WM. Epidemiology of hypertension. Med Clin North Am 1977;61:467-486.
2. Kannel WB, Sorlie P. Hypertension in Framingham. In: Paul O, ed. Epidemiology and Control of Hypertension. Miami: Symposia Specialists, 1975:553-592.
3. Wilhelmsen L. Synergistic effects of risk factors. Clin Exp Hypertens A 1990;12:845-863.
4. Stokes J, Kannel WB, Wolf PA, et al. The relative importance of selected risk factors for various manifestations of cardiovascular disease among men and women from 35 to 64 years old: 30 years of follow-up in the Framingham Study. Circulation 1987;75(Suppl 5):65-73.
5. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: Principal results. Br Med J 1985;291:97-104.
6. Stamler J, Berkson DM, Lindberg HA. Risk factors: Their role in the etiology and pathogenesis of the atherosclerotic diseases. In: Wissler RW, Geer JC, eds. The Pathogenesis of Atherosclerosis. Baltimore, MD: Williams & Wilkins 1972:41-119.
7. De Clerk F. Review. Blood platelets in human essential hypertension. Agents Actions 1986;18:5-6.
8. Landin K, Tengborn L, Smith U. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med 1990;227:273-278.
9. Kjeldsen S, Gjesdal K, Eide I, Aakeson I, Amundsen R, Foss OP, Leren P. Increased β-thromboglobulin in essential hypertension: Interactions between arterial plasma adrenaline, platelet function and blood lipids. Acta Med Scand 1983;213:369-373.
10. Belch JJF, McArdle BM, Burns P, Lowe GDO, Forbes CD. The effects of acute smoking on platelet behaviour, fibrinolysis and haemorheology in habitual smokers. Thromb Haemost 1984;51:6-8.
11. Haire WD, Goldsmith JC, Rasmussen J. Abnormal fibrinolysis in healthy male cigarette smokers: Role of plasminogen activator inhibitors. Am J Hematol 1989;31;36-40.
12. Alessandrini P, McRae J, Feman S, Fitzgerald GA. Thromboxane biosynthesis and platelet function in type I diabetes mellitus. N Engl J Med 1988;319:208-212.
13. Juhan-Vague I, Roul C, Alessi MC, et al. Increased plasminogen activator inhibitor activity in non-insulin dependent diabetic patients-relationship with plasma insulin. Thromb Haemost 1989;61:370-373.
14. Juhan-Vague I, Valadier J, Alessi MC, et al. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemost 1987;57:67-72.
15. Dawson S, Henney A. The status of PAI-1 as a risk factor for arterial and thrombotic disease: A review. Atherosclerosis 1992;95:105-117.
16. Winther K. The effects of β-blockade on platelet function and fibrinolytic activity. J Cardiovasc Pharmacol 1987; 10(Suppl 2):94-98.
17. Birkebaek NH, Vejby-Christen H, Jakobsen P, Winther K. The effect of nifedipine and captopril on platelet activation and prostanoid production in essential hypertension. J Hypertens 1988;6(Suppl 4):S378-S380.
18. Mehta J, Mehta P, Ostrowski N, Crews F. Effects of verapamil on platelet aggregation, ATP release and thromboxane generation. Thromb Res 1983;30:468-475.
19. Winther K, Gleerup G, Hedner T. Enhanced risk of thromboembolic disease in hypertension from platelet hyperfunction and decreased fibrinolytic activity: Has antihypertensive therapy any influence? J Cardiovasc Pharmacol 1992; 19(Suppl 3):S21-S24.
20. Ding Y, Han C, Chou TC, Lai WY, Shiao MF. Effects of the calcium antagonist isradipine on 24-hour ambulatory blood pressure, platelet aggregation, and neutrophil oxygen free radicals in hypertension. J Cardiovasc Pharmacol 1992; 19(Suppl 3):S32-S37.
21. Kirchhof B, Kirchhof U, Etscheid G. Attempts to standardize platelet aggregation measurements: Simplified screening tests. Haemostatis 1990;20:169-180.
22. Born GVR. Aggregation of blood platelets by adenosine disphosphate and its reversal. Nature 1962;927-929.
23. Letter to the editor: Measurements of platelet factor 4 and β-thromboglobulin by an enzyme-linked immunosorbent assay. Clin Chim Acta 1988;175:113-114.
24. Grimaudo V, Hauert J, Bachmann F, Kruithof EKO. Diurnal variation of the fibrinolytic system. Thromb Haemost 1988;59:495-499.
25. Nyrop M, Zweifler AJ. Platelet aggregation in hypertension and the effects of antihypertensive treatment. J Hypertens 1988;6:263-269.
26. Gleerup G, Winther K. Decreased fibrinolytic activity and increased platelet function in hypertension: Possible influence of calcium antagonism. Am J Hypertens 1991;4: 168S-171S.
27. Smith U, Gudbjornsdottir S, Landin K. Hypertension as a metabolic disorder - an overview. J Intern Med 1991; 229(Suppl 2):1-7.
28. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke and coronary heart disease. Part 1. Prolonged difference in blood pressure: Prospective observational studies corrected for the regression dilution bias. Lancet 1990;i:765-774.
29. Wolf PA, Dawber TR, Thomas EH, Cotton T, Nickson RJ. The epidemiology of atherothrombotic brain infarction (ABI): The Framingham Study. Stroke 1977;8:4-9.
30. Meade TW, Chakrabarti R, Hainsen AP, North WRS, Stirling Y. Characteristics affecting fibrinolytic activity and plasma fibrinogen concentrations. Br Med J 1979;20: 153-156.
31. Auwerx J, Bouillon R, Collen D, Geboers J. Tissue-type plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 1988;8:68-72.
32. Sagel J, Colwell JA, Crook L. Lamins M. Increased platelet aggregation in early diabetes mellitus. Ann Intern Med 1975;82:733-738.
33. Colwell JA, Halushka PV, Sarji K, Levine J, Sagel J, Nair RMG. Altered platelet function in diabetes mellitus. Diabetes 1976;25:826-31.
34. Gleerup G, Hedner T, Hjorting Hansen E, Winther K. Does antihypertensive therapy affect the natural protection against thrombosis? J Cardiovasc Pharmacol 1991;18(Suppl 3):S34-S36.
35. Ding Y, Han C, Chou T, Lai W, Shiao M. Effect of isradipine on platelet aggregation and oxygen free radicals in hypertension. J Hypertens 1991;9(Suppl 6):S370-S371.
36. Sinziger H, Virgolini I, Rauscha F, Fitscha P, Grady JO. Isradipine improves platelet function in hypertensives. Eur J Clin Pharmacol 1992;42:43-46.
37. Weiss K, Fitscha P, Grady JO, Sinziger H. Isradipine: A potent calcium blocker with beneficial effects on platelet function and vascular prostacyclin production. Thromb Res 1989;54:311-317.
38. Sinziger H, Virgolini I, Grady JO, et al. Aspirin abolishes the decreased low-density lipoprotein (LDL) entry into the rabbit arterial wall induced by the calcium channel blocker isradipine. Eicosanoids 1992;5:13-16.
39. Muiesan G, Agabiti E, Muiesan ML, Castellano M, Beschi M. Adrenergic activity and left ventricular function during treatment of essential hypertension with calcium antagonist. Am J Cardiol 1986;57:44D-49D.